Advances in the Diagnosis of Primary Aldosteronism

SPONSORED BY: DiaSorin, DiaSorin
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Clinical Chemistry Postdoctoral Fellow, Vanderbilt University Medical Center
      Dr. Joesph Wiencek, PhD completed his undergraduate education at The Ohio State University. Following this he received his Ph.D. in the joint Clinical - Bioanalytical Chemistry doctoral program through Cleveland State University and the Cleveland Clinic. Secondary to his graduate research in hematology and coagulation, he completed a comprehensive clinical chemistry internship at the Cleveland Clinic's Pathology and Laboratory Medicine Institute. Currently, Dr. Wiencek is a second year Clinical Chemistry Fellow at Vanderbilt University School of Medicine. His clinical interests revolve around endocrinology and pediatric clinical chemistry. Dr. Wiencek, also, serves as an officer for several divisions within the American Association for Clinical Chemistry.
    • Associate Professor of Pathology and Laboratory Medicine, Medical Director of Chemistry, University of Kentucky Medical Center
        Dr. Alison Woodworth PhD, DABCC, FACB is currently Associate Professor of Pathology and Laboratory Medicine at the University of Kentucky Medical Center. Where she is also Medical Director of Clinical Chemistry. She is a Diplomate of the American Board of Clinical Chemistry and currently serves as a director on the ABCC exam committee. She is actively involved in teaching and has directed the clinical chemistry fellowship training program. Dr. Woodworth is actively involved in several national organizations including AACC and ACLPS. She serves on the board of directors and as the Chair of the editorial board of the Scientific Shorts Committee for the AACC Academy as well as on the executive council of ACLPS. Her noteworthy contributions to clinical and translational research in the areas of sepsis, endocrinology, and Maternal/Fetal Medicine have resulted in multiple publications and awards.


      Primary Aldosteronism (PA) is a group of disorders characterized by inappropriate aldosterone production. PA is commonly caused by an adrenal adenoma, or by hyperplasia of the adrenal zona glomerulosa that can be either unilateral or bilateral. The disorder accounts for up to 15% of total hypertensive patients making it a serious public health concern. Patients with PA have a higher cardiovascular morbidity and mortality risk when compared with those with essential hypertension matched for age, sex and blood pressure. Fortunately, timely diagnosis through laboratory testing leads to a potentially treatable or curable disorder. The Endocrine Society guidelines recommend a multi-tiered approach with both screening and provocative confirmatory testing for the diagnosis of PA. The guidelines recommend the plasma aldosterone/plasma renin ratio (ARR) as the most reliable screening test for PA. Traditionally, renin is measured by a plasma renin activity (PRA) radioimmunoassay or liquid chromatography tandem mass spectrometry (LC-MS/MS). However, newer quantitative renin mass immunoassays offer benefits of walk-away automation, better turnaround times and stability with comparable diagnostic accuracy to PRA.  In this webinar, we will discuss the updates to the Endocrine Society practice guidelines for the management of PA and present data from a large study assessing the diagnostic accuracy of different Renin assays to predict PA in hypertensive patients.

      Learning Objectives:

      • Discuss the diagnostic algorithm for the work up of Primary Aldosteronism from the latest Endocrine Society Practice Guidelines
      • Identify the importance of screening for Primary Aldosteronism (PA) in patients with hypertension
      • Assess the diagnostic accuracy of the renin mass assay to predict PA among hypertensive patients

      Show Resources
      Loading Comments...